We first aimed to confirm the clinical relevance of β-catenin and FOXO3a by analyzing the overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) of CRC patients (n = 177). The gene discussed is FOXO3; the disease is colorectal carcinoma.